Biogen Inc. (BIIB)

239.30
NASDAQ
Prev Close 236.67
Day Low/High 233.80 / 239.47
52 Wk Low/High 217.10 / 468.55
Exchange NASDAQ
Shares Outstanding 146.89B
Market Cap 34.77B
P/E Ratio 8.89
Div & Yield N.A. (N.A)
Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Biotechs Rally on Pfizer/Medivation Deal

The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...

Bret Jensen Reporting for Duty

Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...

It's Time to Go Short Stocks; Here Are Some Ideas

It's Time to Go Short Stocks; Here Are Some Ideas

Besides Tesla, Twitter and Biogen make good candidates.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

Endo International Shares Climb on Earnings Beat

Endo International Shares Climb on Earnings Beat

Shares of the specialty-healthcare firm climbed on better-than-expected profits for the second quarter.

Watch Gilead for Buying Opportunities

Watch Gilead for Buying Opportunities

There is a case for a low already being in place.

Biogen Tie-Up Would Still Bring Premium, Analysts Say

Biogen Tie-Up Would Still Bring Premium, Analysts Say

Deal rumors are deflating, but a takeover bid could reward holdouts.

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

Cramer: Does It Have to Be All About Oil?

Cramer: Does It Have to Be All About Oil?

That's a shaky basis for a rally.

Closing Bell: Biogen Spikes on Takeover Talk; Crude Closes Near Four-Month Low

Closing Bell: Biogen Spikes on Takeover Talk; Crude Closes Near Four-Month Low

U.S. stocks hold near lows through to the end of the session as crude oil closes below $40 a barrel, its lowest level since April, on continued supply worries.

Biogen Spikes as Allergan Tie-Up Rumors Flare Up Again

Biogen Spikes as Allergan Tie-Up Rumors Flare Up Again

The companies were also the subject of merger rumors back in April.

Approach Biogen With Caution

Approach Biogen With Caution

The drug stock has soared sharply higher in recent weeks; how it behaves on a pullback will be key.

Biogen and Ionis See Boost From Clinical Drug Trial

Biogen and Ionis See Boost From Clinical Drug Trial

Shares of Biogen and Ionis Pharmaceuticals were higher Monday after announcing that their treatment for a rare, children's spine disorder had some positive results.

Trending Tickers: MUR, DO, BIIB, VZ

Trending Tickers: MUR, DO, BIIB, VZ

As crude oil falls below $40, stocks tied to oil are reeling.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Midday Report: Biogen Lifts Biotech; U.S. Stocks Break Higher

Midday Report: Biogen Lifts Biotech; U.S. Stocks Break Higher

Stocks break free of range-bound trading by late morning as gains in biotech help to offset losses in energy.

Where Is the Insider Buying?

The market is off its worst levels of the day. Big biotech and biopharma are providing strength today, with Biogen , Gilead Sciences and Mylan all sporting solid gains in a down market. Energy has made a bit of a comeback, but still is down nearly 2...

I'm Bullish on Biotechs

The market continues to trade lower as we late morning, with Tobira Therapeutics serving as the "disaster du jour" in the small-cap biotech space. This stock is trading down some 60% after its midstage compound targeting non-alcoholic steatohepatiti...

Midday Report: Existing Home Sales at Best Since 2007; U.S. Stocks Mixed

Midday Report: Existing Home Sales at Best Since 2007; U.S. Stocks Mixed

Quarterly reports continued to come in at breakneck speed with some of the key highlights including American Express, eBay, General Motors, Southwest Airlines, and Biogen.

Biogen Shares Climb on Earnings Beat, CEO Departure

Biogen Shares Climb on Earnings Beat, CEO Departure

Biogen shares could be on a turnaround trajectory after a year of disappointments.

Morning Movers: GM, JOY, RLYP, BIIB

Morning Movers: GM, JOY, RLYP, BIIB

General Motors crushed Wall Street earnings estimates before the opening bell.

What to Watch This Week: Bank of America, Goldman Sachs, Netflix and Yahoo! Report Earnings

What to Watch This Week: Bank of America, Goldman Sachs, Netflix and Yahoo! Report Earnings

For the week of July 18, the earnings parade continues, with dozens of major companies reporting financial results.

Here's Why Action Alerts PLUS Exited Biogen Today

Here's Why Action Alerts PLUS Exited Biogen Today

The charitable trust sold out of its position in Biogen while also trimming its holdings in Target.

WhiteWave Rides Another Downgrade

WhiteWave Rides Another Downgrade

The organic food producer was downgraded to 'Hold' by Jefferies.

Beaten-Down Biogen May Be Biotech Bargain

Beaten-Down Biogen May Be Biotech Bargain

Any turn in the fundamentals or sentiment easily can send these shares trading much higher from here.

Biogen: Quality at a Discount

Biogen: Quality at a Discount

Biotechs now offer some great valuations, and BIIB is prime example.

Portfolio Roundup: AAPL, BIIB, COST

Portfolio Roundup: AAPL, BIIB, COST

Action Alerts PLUS holdings Apple, Biogen and Costco make moves in the market with Brexit concerns, drug prospects and overall vulnerability. 

Trader's Daily Notebook: If There's a Bounce, It Won't Last Long

Trader's Daily Notebook: If There's a Bounce, It Won't Last Long

But above all, know your time frame.